{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:56Z","timestamp":1791357296638,"version":"4.3.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.anai.2018.05.022","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T22:38:16Z","timestamp":1527201496000},"page":"552-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-risk drug rashes"],"prefix":"10.1016","volume":"121","author":[{"given":"Sasha A.","family":"Alvarado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mu\u00f1oz-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-1870","authenticated-orcid":false,"given":"Sami L.","family":"Bahna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.05.022_bib0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13601-017-0188-1","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database","volume":"8","author":"Sousa-Pinto","year":"2018","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.anai.2018.05.022_bib0002","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1346-8138.2012.01532.x","article-title":"Distinguishing between erythema multiforme major and Stevens-Johnson syndrome\/toxic epidermal necrolysis immunopathologically","volume":"39","author":"Iwai","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0003","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0004","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaip.2017.02.013","article-title":"Severe cutaneous adverse drug reactions in pediatric patients: A multicenter study","volume":"5","author":"Dibek Misirlioglu","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.05.022_bib0006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients\u2013Treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.anai.2018.05.022_bib0007","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: Building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.05.022_bib0008","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaip.2017.09.001","article-title":"Chronic ocular complications of Stevens-Johnson syndrome associated with causative medications in Korea","volume":"6","author":"Lee","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.05.022_bib0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.burns.2016.07.026","article-title":"Steven Johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience","volume":"43","author":"McCullough","year":"2017","journal-title":"Burns"},{"key":"10.1016\/j.anai.2018.05.022_bib0010","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0011","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: An analysis of triggers and implications for improving prevention","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.anai.2018.05.022_bib0012","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1034\/j.1398-9995.2003.00120.x","article-title":"Severe drug rashes in three siblings simultaneously","volume":"58","author":"Johnson-Reagan","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.05.022_bib0013","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.anai.2016.09.443","article-title":"Antiepilepsy drugs and the immune system","volume":"117","author":"Godhwani","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.05.022_bib0014","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdermsci.2013.10.003","article-title":"Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations","volume":"73","author":"Hsiao","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.anai.2018.05.022_bib0015","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.anai.2018.05.022_bib0016","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0017","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.humimm.2014.09.022","article-title":"HLA-B\u2217 1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population","volume":"75","author":"Aggarwal","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1016\/j.anai.2018.05.022_bib0018","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/epi.12802","article-title":"HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis","volume":"55","author":"Khor","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.anai.2018.05.022_bib0019","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.anai.2018.05.022_bib0020","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0021","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/FPC.0000000000000285","article-title":"Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population","volume":"27","author":"Saksit","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.anai.2018.05.022_bib0022","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.anai.2018.05.022_bib0023","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures","volume":"34","author":"Schneider","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.anai.2018.05.022_bib0024","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.05.022_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6928363","article-title":"Immunohistopathological findings of severe cutaneous adverse drug reactions","volume":"2017","author":"Orime","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.anai.2018.05.022_bib0026","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/1346-8138.12925","article-title":"Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Aihara","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0027","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ijd.13379","article-title":"A retrospective analysis of Stevens-Johnson syndrome\/toxic epidermal necrolysis treated with corticosteroids","volume":"55","author":"Liu","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0028","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for stevens-johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0030","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bjd.12607","article-title":"The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre","volume":"169","author":"Lee","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0031","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0032","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","article-title":"Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China","volume":"33","author":"Zhu","year":"2012","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.anai.2018.05.022_bib0033","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0034","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcrc.2017.07.002","article-title":"Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study","volume":"42","author":"Han","year":"2017","journal-title":"J Crit Care"},{"key":"10.1016\/j.anai.2018.05.022_bib0035","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1097\/GOX.0000000000001221","article-title":"Management of toxic epidermal necrolysis with plasmapheresis and cyclosporine A: our 10 years' experience","volume":"5","author":"Giudice","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.anai.2018.05.022_bib0036","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0037","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2018.05.022_bib0038","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1468-3083.2012.04572.x","article-title":"Umbilical cord mesenchymal stem cell transplantation in drug-induced Stevens-Johnson syndrome","volume":"27","author":"Li","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2018.05.022_bib0039","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0040","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ophtha.2016.04.041","article-title":"New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome","volume":"123","author":"Gregory","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.anai.2018.05.022_bib0041","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ophtha.2015.10.027","article-title":"Adjuvant role of amniotic membrane transplantation in acute ocular Stevens-Johnson syndrome: a randomized control trial","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.anai.2018.05.022_bib0042","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0043","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0044","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction: results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0045","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.alit.2016.04.001","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS): 11 years retrospective study in Thailand","volume":"65","author":"Hiransuthikul","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.anai.2018.05.022_bib0046","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0047","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2015.02.1130","article-title":"Liver injury in patients with DRESS: A clinical study of 72 cases","volume":"72","author":"Lin","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0048","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"155","author":"Peyri\u00e8re","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0049","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2014.10.032","article-title":"Therapeutic management of DRESS: a retrospective study of 38 cases","volume":"72","author":"Funck-Brentano","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamadermatol.2013.6698","article-title":"Prolonged evolution of drug reaction with eosinophilia and systemic symptoms: clinical, virologic, and biological features","volume":"150","author":"Tetart","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0051","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/ijms18061243","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system","volume":"18","author":"Cho","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anai.2018.05.022_bib0052","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00228-017-2250-2","article-title":"Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions","volume":"73","author":"Yampayon","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.anai.2018.05.022_bib0053","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jaip.2017.06.017","article-title":"The 3 Cs of antibiotic allergy-classification, cross-reactivity, and collaboration","volume":"5","author":"Trubiano","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.05.022_bib0054","doi-asserted-by":"crossref","unstructured":"Trubiano JA, Strautins K, Redwood AJ, et al. The combined utility of ex vivo IFN-\u03b3 release enzyme-linked ImmunoSpot assay and In vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions [published online October 31, 2017]. J Allergy Clin Immunol Pract. doi:10.1016\/j.jaip.2017.09.004","DOI":"10.1016\/j.jaip.2017.09.004"},{"key":"10.1016\/j.anai.2018.05.022_bib0055","doi-asserted-by":"crossref","unstructured":"Marcus N, Smuel K, Almog M, et al. Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome [published online November 30, 2017]. J Allergy Clin Immunol Pract. doi:10.1016\/j.jaip.2017.10.016","DOI":"10.1016\/j.jaip.2017.10.016"},{"key":"10.1016\/j.anai.2018.05.022_bib0056","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.148.4.dlt120002-c","article-title":"Poor benefit\/risk balance of intravenous immunoglobulins in DRESS","volume":"148","author":"Joly","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0057","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamadermatol.2016.2220","article-title":"Cyclosporine treatment of drug-induced hypersensitivity syndrome","volume":"152","author":"Kirchhof","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0058","doi-asserted-by":"crossref","unstructured":"Ange N, Alley S, Fernando SL, Coyle L, Yun J. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab [published online November 10, 2017]. J Allergy Clin Immunol Pract. doi:10.1016\/j.jaip.2017.10.020","DOI":"10.1016\/j.jaip.2017.10.020"},{"key":"10.1016\/j.anai.2018.05.022_bib0059","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2010.12.013","article-title":"Fulminant myocarditis as a late sequela of DRESS: two cases","volume":"65","author":"Bourgeois","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0060","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/1346-8138.12770","article-title":"Sequelae in 145 patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR)","volume":"42","author":"Kano","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0061","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/bjd.12456","article-title":"Drug reaction with eosinophilia and systemic symptoms and thyroiditis: human herpesvirus-6, the possible common link","volume":"169","author":"Descamps","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0062","doi-asserted-by":"crossref","first-page":"E2277","DOI":"10.1210\/jc.2012-2054","article-title":"High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome","volume":"97","author":"Onuma","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anai.2018.05.022_bib0063","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000458725","article-title":"Multiple drug hypersensitivity","volume":"172","author":"Pichler","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.anai.2018.05.022_bib0064","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1346-8138.2010.01142.x","article-title":"Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity","volume":"38","author":"Pichler","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0065","first-page":"293","article-title":"Multiple drug hypersensitivity\u2013proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests","volume":"15","author":"Gex-Collet","year":"2005","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.anai.2018.05.022_bib0066","first-page":"275","article-title":"T-cell reactions to drugs in distinct clinical manifestations of drug allergy","volume":"11","author":"Neukomm","year":"2001","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.anai.2018.05.022_bib0067","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jdv.12419","article-title":"Recurrence of drug-induced reactions in DRESS patients","volume":"29","author":"Picard","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2018.05.022_bib0068","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1346-8138.2011.01491.x","article-title":"Case of drug-induced hypersensitivity syndrome involving multiple-drug hypersensitivity","volume":"39","author":"Ogawa","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0069","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2125.2010.03832.x","article-title":"Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicin","volume":"71","author":"Wendland","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.anai.2018.05.022_bib0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1398-9995.2011.02720.x","article-title":"Multiple drug hypersensitivity: normal Treg cell function but enhanced in vivo activation of drug-specific T cells","volume":"67","author":"Daubner","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.05.022_bib0071","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.resinv.2012.04.004","article-title":"Two cases of tuberculosis with multiple drug hypersensitivity after drug-induced hypersensitivity syndrome","volume":"50","author":"Sekine","year":"2012","journal-title":"Respir Investig"},{"key":"10.1016\/j.anai.2018.05.022_bib0072","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/ACI.0000000000000288","article-title":"Relapsing drug-induced hypersensitivity syndrome","volume":"16","author":"Tan","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.05.022_bib0073","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/ijms17081214","article-title":"Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy","volume":"17","author":"Feldmeyer","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anai.2018.05.022_bib0074","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): A review and update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.anai.2018.05.022_bib0076","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s13555-017-0206-1","article-title":"Acute localized exanthematous pustulosis (ALEP): review of literature with report of case caused by amoxicillin-clavulanic acid","volume":"7","author":"Villani","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.anai.2018.05.022_bib0077","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0078","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-4632.2010.04313.x","article-title":"Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore","volume":"49","author":"Lee","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0079","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2015.10.030","article-title":"Dermoscopy as an auxiliary tool in the early differential diagnosis of acute generalized exanthematous pustulosis (AGEP) and exanthematous (morbilliform) drug eruption","volume":"74","author":"Errichetti","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0080","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP): results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0081","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jdcr.2014.09.004","article-title":"Acute generalized exanthematous pustulosis associated with primary Epstein-Barr virus infection","volume":"1","author":"Ropars","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.anai.2018.05.022_bib0082","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000471842","article-title":"Rapid involution of pustules during topical steroid treatment of acute generalized exanthematous pustulosis","volume":"9","author":"Kley","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0083","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/260928","article-title":"Five-year retrospective review of acute generalized exanthematous pustulosis","volume":"2015","author":"Thienvibul","year":"2015","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.anai.2018.05.022_bib0084","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2014.01.011","article-title":"Diagnosis and classification of pemphigus and bullous pemphigoid","volume":"13","author":"Kershenovich","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.anai.2018.05.022_bib0085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2018.05.022_bib0086","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-016-3679-1","article-title":"Drug-induced bullous pemphigoid","volume":"31","author":"Kanahara","year":"2016","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.anai.2018.05.022_bib0087","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjd.15195","article-title":"The association between drugs and bullous pemphigoid","volume":"176","author":"Tan","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2018.05.022_bib0088","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/fcp.12083","article-title":"Bullous pemphigoid induced by vildagliptin: a report of three cases","volume":"29","author":"Bene","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.anai.2018.05.022_bib0089","article-title":"Metronidazole-induced bullous pemphigoid: a case report","volume":"9","author":"Moitra","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.anai.2018.05.022_bib0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.anai.2018.05.022_bib0091","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","article-title":"Immunosuppressive therapy for autoimmune bullous diseases","volume":"30","author":"Meurer","year":"2012","journal-title":"Clin Dermatol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618303880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618303880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:20:15Z","timestamp":1761052815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120618303880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1081120618303880"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.05.022","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-risk drug rashes","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}